ClinicalTrials.gg
TerminatedNCT00410566Updated Mar 19, 2015

Safety Study of rhASM Enzyme Replacement Therapy in Adults With Acid Sphingomyelinase Deficiency (Niemann-Pick Disease)

A Phase 1 interventional study of rhASM and rhASM in Acid Sphingomyelinase Deficiency and Niemann-Pick Disease, sponsored by Genzyme, a Sanofi Company. Terminated at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2015-03-19.

Sponsored by Genzyme, a Sanofi Company (part of Sanofi) · Phase 1, Interventional, and Treatment

Why this study was terminated
Terminated by sponsor - Single dose safety objective achieved.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
11
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies in Niemann-Pick Diseases with a site in United States — 3 open to participants now, 3 under way, none of them phase 3. Niemann-Pick Diseases · United States.

Started
2006
the only one that year
Phase 1
4 of 17
none open now
Registered
5th of 17
by date
Lead sponsor
2 of 17
Genzyme, a Sanofi Company

Among the 17 studies in Niemann-Pick Diseases with a site in United States, this one is the only one that started in 2006, is one of 4 in phase 1, and was the 5th registered.

Niemann-Pick Diseases

28 studies on the registry are indexed under Niemann-Pick Diseases; 7 are open to participants now.

Browse Niemann-Pick Diseases studies →

Open to participants now

3 of the 17 studies in Niemann-Pick Diseases with a site in United States are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 6 Niemann-Pick Diseases studies recruiting now, 3 set no upper age limit and 2 stop at 75 or younger; 4 take children under 18; 1 takes healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Niemann-Pick Diseases with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine the safe range of single doses of rhASM administered to adults with ASM deficiency.

Read the detailed description

ASM deficiency (ASMD), also known as Niemann-Pick A and B disease, is a rare genetic disorder in which reduced activity of the lysosomal enzyme, ASM, leads to the accumulation of sphingomyelin primarily in macrophages throughout the body. This deficiency results in characteristic features such as hepatosplenomegaly, thrombocytopenia, interstitial lung disease, growth retardation, coronary artery disease, fatigue, and in severe cases, neurodegeneration with death in early childhood. There is no specific treatment for this disease. This Phase 1 safety study will seek to enroll a minimum of 12 and a maximum of 30 eligible adults patients with ASMD with each patient participating for approximately 7 weeks.

03

Conditions studied

  • Acid Sphingomyelinase Deficiency
  • Niemann-Pick Disease

Keywords

  • Acid sphingomyelinase deficiency
  • Niemann-Pick disease
  • Lysosomal storage disorder
  • Enzyme replacement therapy
  • Treatment
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed, by the patient or legal guardian prior to performing any study-related procedures;
  • Have ≤ 0.2 nmol/hr/mg protein ASM activity in peripheral leukocytes, as measured by the reference laboratory;
  • Have a diffusing capacity (DLco) > 30% of the predicted normal value;
  • Have a spleen volume ≥ 2x normal
  • Female patients of must have a serum pregnancy test negative for β-hCG and agree to use a reliable method for the duration of the study.

Exclusion criteria

Exclusion Criteria:

  • Is pregnant or lactating;
  • Has received an drug within 30 days prior to study enrollment;
  • Has a medical condition, including serious intercurrent illness, active or C or (HIV) infection, cirrhosis, > stage 3 liver fibrosis, >1.5, count \< 60.0x10\^3/µL, significant cardiac disease (e.g. pulmonary artery pressure > 40 mm Hg, moderate or severe valvular dysfunction, or \< 40% by echocardiography (ECHO)), or any other extenuating circumstances that may significantly interfere with study compliance including all prescribed evaluations and follow-up activities;
  • Has had a major organ transplant (e.g. bone marrow or liver);
  • Has had a total splenectomy;
  • Has an (ALT) or aspartate aminotransferase (AST) value >250 IU/L or a total >3.6 mg/dL;
  • Is unwilling or unable to avoid the use of alcohol, medications that may decrease rhASM activity, medications or herbal supplements that may cause or prolong bleeding, and the use of medications or herbal supplements with potential hepatoxicity within 14 days prior to and 28 days afte the rhASM infusion.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
11 participants (actual)

Study arms

  • Experimental
    1

    Drug: rhASM

  • Experimental
    2

    Drug: rhASM

  • Experimental
    3

    Drug: rhASM

  • Experimental
    4

    Drug: rhASM

  • Experimental
    5

    Drug: rhASM

Interventions

  • DrugrhASM

    Single dose of 0.03mg/kg body weight IV

  • DrugrhASM

    Single dose of 0.1mg/kg body weight IV

  • DrugrhASM

    Single dose of 0.3mg/kg body weight IV

  • DrugrhASM

    Single dose of 0.6mg/kg body weight IV

  • DrugrhASM

    Single dose of 1.0mg/kg body weight IV

06

What researchers measure

Primary outcomes

  1. Safety assessments via physical exam,AE reporting,telemetry heartrate monitoring,ECG,ECHO,clinical lab evaluations,liver and adrenal function tests,cytokine testing,adrenal hormone levels,lipid profile,chest Xrays,liver biopsies,MRI of internal

    Time frame: Pre-, During-, and Post-infusion (up to 72 hrs); 14 day and 28 day follow-up visit

  2. Immune Response Measure

    Time frame: Pre-infusion and final visit (Day 28)

Secondary outcomes

  1. PK measurements

    Time frame: Pre- and Post-infusion up to 72 hrs.

07

Study locations

1 site
  • New York, New York 10029, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2006, a primary completion of Mar 2009 and a completion of Apr 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2006
First posted
Dec 13, 2006
Start
Dec 2006
Primary completionActual
Mar 2009
CompletionActual
Apr 2009
Last update
Mar 19, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00410566
Responsible party
Sponsor
First posted
Dec 13, 2006
Start date
Dec 2006
Primary completion
Mar 2009
Completion
Apr 2009
Last update
Mar 19, 2015

Study contacts

Medical Monitor
study director · Genzyme, a Sanofi Company

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Olipudase alfa

Start the discussion